Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11788600 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KCNH2KDM4ECYP2C9TP53 | |
| SCHEMBL20320680 | 0.71 | ALDH1A1 (0.37) | ALDH1A1TLR8TLR7SMN1; SMN2CYP2C9 | |
| SCHEMBL8581050 | 0.71 | ALDH1A1 (0.39) | ALDH1A1KDM4ECYP2C9MAPT | |
| SCHEMBL3252265 | 0.70 | NPSR1 (0.38) | ALDH1A1SMN1; SMN2KDM4ERAB9APOLB | |
| Hexane SCHEMBL28379586 | 0.67 | CASP1 (0.48) | TLR8TLR7DHFR | |
| SCHEMBL468531 | 0.67 | CYP2D6 (0.53) | ALDH1A1TLR8TLR7DHFRKCNH2 | |
| SCHEMBL11335612 | 0.67 | SMN1; SMN2 (0.53) | ALDH1A1TLR8TLR7SMN1; SMN2DHFR | |
| SCHEMBL28331464 | 0.67 | ALDH1A1 (0.50) | ALDH1A1TLR8TLR7SMN1; SMN2DHFR | |
| SCHEMBL627048 | 0.67 | ALDH1A1 (0.46) | ALDH1A1TLR8TLR7DHFRKCNH2 | |
| SCHEMBL9798228 | 0.67 | SMN1; SMN2 (0.53) | ALDH1A1TLR8TLR7SMN1; SMN2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165070-B1 | THIADIAZOLYL UREA OR THIOUREA DERIVATIVES FOR ANTIVIRAL TREATMENT | UAF TECHNOLOGIES AND RES LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1165074-B1 | VIRAL TREATMENT | UAF TECHNOLOGIES AND RES LLC (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6410575-B2 | ADMINISTERING (5-ARYL-1,2,4-THIADIAZOL)-3-YL THIOUREA AND UREA DERIVATIVES TO TREAT HEPATITIS, HIV AND KAPOSI SARCOMA, AS VIRICIDES AND ANTICARCINOGENIC AGENTS | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-6384064-B2 | HUMAN IMMUNODEFICIENCY SYNDRONE, HEPATITIS VIRUS | THE PROCTER & GAMBLE COMPANY | 2002-05-07 | — | — | US | disclosed |
| US-6340696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF COMBINATION OF (5-ARYL-1,2,4-THIADIAZOL)-3-YL THIOUREA DERIVATIVE OR (5-ARYL-1,2,4-THIADIAZOL)-3-YL UREA DERIVATIVE AND RIBAVIRIN AND/OR INTERFERON | THE PROCTER & GAMBLE COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1165070-A1 | THIADIAZOLYL UREA OR THIOUREA DERIVATITIVES FOR ANTIVIRAL TREATMENT | The Procter & Gamble Company (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1165074-A2 | VIRAL TREATMENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010034358-A1 | Viral treatment | THE PROTECTOR & GAMBLE COMPANY | 2001-10-25 | — | — | US | disclosed |
| US-20010031773-A1 | Viral treatment | THE PROCTER & GAMBLE COMPANY | 2001-10-18 | — | — | US | disclosed |
| US-6258831-B1 | THIOUREAS AND UREAS DERIVATIVES WITH 5-ARYL-1,2,4-TRIAZOLE | THE PROCTER & GAMBLE COMPANY | 2001-07-10 | — | — | US | disclosed |
| US-6245788-B1 | USING 5-ARYL-1,2,4-TRIADAZOL-3-YL (THIO)UREA COMPOUND | THE PROCTER & GAMBLE COMPANY | 2001-06-12 | — | — | US | disclosed |
| WO-2000057869-A2 | VIRAL TREATMENT | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000057878-A1 | THIADIAZOLYL UREA OR THIOUREA DERIVATIVES FOR ANTIVIRAL TREATMENT | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034358-A1 | Viral treatment | TPMT, NSUN2, XDH | ALDH1A1 1300/4885TLR8 3472/4885TLR7 1307/4885 |
| US-20010031773-A1 | Viral treatment | TK1, HK1, RPL5 | ALDH1A1 901/4885TLR8 3307/4885TLR7 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.